Last updated on September 2017

A phase 2A, randomized, double-blind, placebo-controoled, study to evaluate safety and efficacy of PF-06700841 in subjects with moderate to severe plaque psoriasis.


Brief description of study

A phase 2A, randomized, double-blind, placebo-controoled, study to evaluate safety and efficacy of PF-06700841 in subjects with moderate to severe plaque psoriasis.

Detailed Study Description

12 week double-blind study with a 8 week followup.

Clinical Study Identifier: TX152867

Contact Investigators or Research Sites near you

Start Over

Jenna Spatz

Psoriasis Treatment Center of Central New Jersey
East Windsor, NJ USA
  Connect »